Variant Bio has entered a multi-year research partnership with Novo Nordisk, focusing on the identification of new targets to treat metabolic conditions. Leveraging Variant’s ‘VB-Inference ...

Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic disease targets.

A rooftop deck at Variant Bio’s Seattle offices have a view of the city’s landmark Space Needle. (Cory Parris Photo) Variant Bio today announced a partnership with Novo Nordisk for disease ...

Commercial terms include an upfront payment and additional near-term R&D funding totaling up to $50 million, plus potential option and milestone payments SEATTLE, Jan. 7, 2025 /PRNewswire ...

Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from diverse populations.

SEATTLE, Jan. 7, 2025 /PRNewswire/ -- Variant Bio, a genomics-driven drug discovery company, today announced a multi-year research collaboration with Novo Nordisk to discover novel targets for the ...

"Metabolic disease - including obesity - affects people all over the world, yet newer targets with genetic evidence are primarily based on studies with European-ancestry populations. As a result ...

Under the terms of the agreement, Novo Nordisk will pay Variant Bio an upfront payment and additional near-term R&D funding totaling up to $50 million, plus potential option and milestone payments ...

Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populations.